For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

ReBoost Nasal Spray has been recalled nationwide after tests found mold and bacteria, prompting FDA warnings of possible ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up ...

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

Tirzepatide, used in Mounjaro and Zepbound, can produce dramatic weight loss and improvements in blood pressure, cholesterol ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...